Ovarian Function at Advanced Reproductive Age Clinical Trial
Official title:
Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age
The goal of the investigators research is to explore energy production of the ovarian follicle in older reproductive age women at the time of oocyte retrieval.
| Status | Not yet recruiting |
| Enrollment | 100 |
| Est. completion date | September 2014 |
| Est. primary completion date | September 2014 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 38 Years to 43 Years |
| Eligibility |
Inclusion Criteria: - Age 38-43 years at the time of enrollment - Diagnosis of primary infertility Exclusion Criteria: - Body mass index (BMI) > 30 kg/m2 - Early follicular phase (day 2-4) serum FSH level > 20 mIU/ml. - Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography - Any current use of systemic steroid medication or any infertility treatment within 3 months of study enrollment. - Any contraindication to being pregnant and carrying a pregnancy to term. - Contraindication for the use of CoQ10, or fertility medications. - Any ovarian or abdominal abnormality that may interfere with adequate TVS evaluation. - Absence of one or two ovaries - Clinically relevant systemic disease (e.g., Insulin-dependent diabetes, adrenal dysfunction, organic intracranial lesion, polycystic ovarian syndrome, hyperprolactinemia, or hypothalamic tumor) or serious illness (Neoplasia). - History (within past 12 months) or current abuse of alcohol or drugs. - Administration of any investigational drugs within three months prior to study enrollment. - Any medical condition that may interfere with the absorption, distribution, metabolism or excretion of the study drugs, gastrointestinal diseases, mal absorption syndromes and liver dysfunction - Unexplained gynecological bleeding. - Ejaculated sperm is not sufficient for ICSI - Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study. - Abnormal COH screening blood done for both partners, including: prolactin, thyroid stimulating hormone, HIV serology, Hepatitis B and C serology, Rubella, group and screen and syphilis serology prior to participation in study. - Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial. - The concurrent use of any of the following drugs: - Daunorubicin, Doxorubicin, Blood Pressure Medications, Warfarin, Timolol, atorvastatin, cerivastatin, lovastatin, pravastatin, simvastatin gemfibrozil, tricyclic antidepressant medications (including amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine) multivitamins or any vitamin supplementation except Folic acid. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Israel | Hadassah Medical Organization | Jerusalem |
| Lead Sponsor | Collaborator |
|---|---|
| Hadassah Medical Organization |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Co Enzyme Q10 levels in maternal serum by HPLC | 2 years | No | |
| Primary | level of ATP production | 2 years | No | |
| Primary | Steriodogenesis associated enzymatic activity | 2 years | No | |
| Secondary | Ovarian Response | 2 years | No | |
| Secondary | Embryo quality | 2 years | No | |
| Secondary | cumulative pregnancy rate per retrieval | 2 years | No | |
| Secondary | cumulative live birth rate per retrieval | 2 years | No |